Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
Prostate artery embolisation (PAE) is a minimally invasive alternative to surgical resection, which aims to shrink the prostate gland rather than remove it. In PAE, an interventional radiologist inserts a catheter into the femoral artery at the top of the leg, and guides the catheter to the prostate arteries. A solution of microscopic particles is injected through the catheter, which mechanically block the prostate arteries and partially reduce the blood supply. There are four different types of embolisation agents (all CE-marked, none with FDA approval) that can be used in PAE, which vary in size and material. A total of three comparative studies with 306 patients are available for analysis of efficacy; the included RCTs make contradictory statements regarding improvements in IPSS and HRQoL after 12 months. The most commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available.
|Item Type:||Decision Support Document|
|Keywords:||Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), prostate artery embolisation (PAE)|
|Subjects:||WB Practice of medicine > WB 300-962 Therapeutics|
WO Surgery > WO 500-517 Operative surgical procedures. Techniques
WJ Urogenital system > WJ 700-875 Male genitalia
W Health professions > W 100-275 Medical, dental and pharmaceutical service plans
WO Surgery > WO 505 Minimally invasive surgical procedures
|Series Name:||Decision Support Document 105|
|Deposited on:||17 Jul 2017 12:05|
|Last Modified:||17 Jul 2017 12:05|
Repository Staff Only: item control page